Novo Nordisk ties up with Emcure to expand reach of weight-loss drug semaglutide in India

Novo Nordisk has partnered with Emcure Pharma to distribute and market its diabetes and weight loss injection semaglutide ...
Zacks.com on MSN

Will Lower GLP-1 Prices Undermine Novo Nordisk's Near-Term Outlook?

NVO's new U.S. pricing deal for Ozempic and Wegovy expands access but adds uncertainty to its growth and profit outlook.

NVO: Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera

Novo Nordisk (NYSE:NVO) climbs about 2% on early Monday after it says it will not raise its offer for Metsera (NASDAQ:MTSR), ...

Novo Nordisk ropes in Emcure Pharma to roll out weight loss drug Poviztra

Danish drugmaker Novo Nordisk announced a partnership with Emcure Pharma on Monday to launch its Poviztra, semaglutide injection 2.4 mg, in India. Poviztra is the second brand of its weight loss drug ...

Novo Nordisk shares rise on investor relief after it exits Metsera bid

COPENHAGEN (Reuters) -Shares in Novo Nordisk rose on Monday after the Wegovy maker lost out to Pfizer in a $10 billion ...

Pfizer wins obesity drug prize, with Trump administration assist

Pfizer Inc. chief executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma ...
Virginia Business

Metsera falls after accepting up to $10 billion offer from Pfizer

Pfizer wins a $10 billion deal for weight-loss drugmaker Metsera, ending its bidding war with Danish rival Novo Nordisk.